646 related articles for article (PubMed ID: 27022975)
21. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
22. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
23. An Update on MDMX and Dual MDM2/X Inhibitors.
Espadinha M; Barcherini V; Lopes EA; Santos MMM
Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
[TBL] [Abstract][Full Text] [Related]
24. MDMX: from bench to bedside.
Marine JC; Dyer MA; Jochemsen AG
J Cell Sci; 2007 Feb; 120(Pt 3):371-8. PubMed ID: 17251377
[TBL] [Abstract][Full Text] [Related]
25. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
Wang X; Wang J; Jiang X
J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037
[TBL] [Abstract][Full Text] [Related]
26. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
27. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
28. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
[TBL] [Abstract][Full Text] [Related]
29. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
30. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
31. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
32. Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain.
Ilic VK; Egorova O; Tsang E; Gatto M; Wen Y; Zhao Y; Sheng Y
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625571
[TBL] [Abstract][Full Text] [Related]
33. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
34. The roles and regulation of MDM2 and MDMX: it is not just about p53.
Klein AM; de Queiroz RM; Venkatesh D; Prives C
Genes Dev; 2021 May; 35(9-10):575-601. PubMed ID: 33888565
[TBL] [Abstract][Full Text] [Related]
35. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
[TBL] [Abstract][Full Text] [Related]
36. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.
Wasylishen AR; Lozano G
Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329033
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
38. Mdm2 and MdmX: Partners in p53 Destruction.
Manfredi JJ
Cancer Res; 2021 Apr; 81(7):1633-1634. PubMed ID: 34003788
[TBL] [Abstract][Full Text] [Related]
39. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
40. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]